G1 Therapeutics
Biopharmaceutical company focused on development of therapies to reduce chemotherapy-induced myelosuppression and improve outcomes in cancer patients. The site emphasizes clinical and translational research, publications, and channels for safety reporting and scientific communications.
Industries
Nr. of Employees
medium (51-250)
G1 Therapeutics
Research Triangle Park, North Carolina, United States
Products
CDK4/6 inhibitor clinical candidate for myelopreservation
Clinical-stage small-molecule CDK4/6 inhibitor developed to protect hematopoietic cells from chemotherapy-induced myelosuppression and to modulate immune responses.
CDK4/6 inhibitor clinical candidate for myelopreservation
Clinical-stage small-molecule CDK4/6 inhibitor developed to protect hematopoietic cells from chemotherapy-induced myelosuppression and to modulate immune responses.
Expertise Areas
- Clinical trial management
- Oncology drug development (CDK4/6 inhibitor focus)
- Translational immuno-oncology
- Pharmacokinetics / pharmacodynamics
Key Technologies
- Small-molecule kinase inhibition (CDK4/6)
- Preclinical tumor models
- Pharmacokinetic / pharmacodynamic (PK/PD) methods
- Immune profiling assays
News & Updates
ASCO 2024 poster reporting updated phase 2 safety and efficacy results for a CDK4/6 inhibitor administered prior to antibody-drug conjugate therapy in mTNBC.
Multicenter randomized phase 2 clinical trial reporting effects on survival and myeloprotection (published in a peer-reviewed oncology journal).
Phase II randomized trial evaluating myelopreservation and outcomes when a CDK4/6 inhibitor is given prior to chemotherapy ± immune checkpoint inhibitor.
ASCO 2024 poster reporting updated phase 2 safety and efficacy results for a CDK4/6 inhibitor administered prior to antibody-drug conjugate therapy in mTNBC.
Multicenter randomized phase 2 clinical trial reporting effects on survival and myeloprotection (published in a peer-reviewed oncology journal).
Phase II randomized trial evaluating myelopreservation and outcomes when a CDK4/6 inhibitor is given prior to chemotherapy ± immune checkpoint inhibitor.